Development of L-Asparaginase biobetters: Current research status and review of the desirable quality profiles

L-Asparaginase (ASNase) is a vital component of the first line treatment of acute lymphoblastic leukemia (ALL), an aggressive type of blood cancer expected to afflict over 53,000 people worldwide by 2020. More recently, ASNase has also been shown to have potential for preventing metastasis from soli...

Full description

Saved in:
Bibliographic Details
Main Authors: Larissa P. Brumano, Francisco Vitor S. da Silva, Tales Alexandre Costa-Silva, Alexsandra C. Apolinario, Joao Henrique P. Santos, Eduardo K. Kleingesinds, Gisele Monteiro, Carlota D. Rangel-Yagui, Brahim Benyahia, Adalberto P. Junior
Format: Default Article
Published: 2019
Subjects:
Chemical engineering not elsewhere classified
L-asparaginase
Quality-by-design
Biobetters
Protein engineering
PEGylation
Nanobiotechnology
Acute lymphoblastic leukemia
Site-directed mutagenesis
Chemical Engineering not elsewhere classified
Online Access:https://hdl.handle.net/2134/36598
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://hdl.handle.net/2134/36598

Similar Items